SK Bioscience Co Ltd (302440) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SK Bioscience Co Ltd (302440) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩20.65 Billion ≈ $14.00 Million USD) by net assets (₩2.07 Trillion ≈ $1.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 302440 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
SK Bioscience Co Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how SK Bioscience Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SK Bioscience Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SK Bioscience Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
N/A |
|
Cimpress NV
NASDAQ:CMPR
|
0.035x |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
0.002x |
|
Northern Oil & Gas Inc
NYSE:NOG
|
0.181x |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
-0.081x |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
-0.132x |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
0.057x |
|
HENSOLDT AG UNSP. ADS
F:HAG0
|
N/A |
Annual Cash Flow Conversion Efficiency for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of SK Bioscience Co Ltd from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see how much is SK Bioscience Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩2.02 Trillion ≈ $1.37 Billion |
₩-128.02 Billion ≈ $-86.76 Million |
-0.063x | -467.52% |
| 2023-12-31 | ₩1.70 Trillion ≈ $1.15 Billion |
₩29.35 Billion ≈ $19.89 Million |
0.017x | +124.01% |
| 2022-12-31 | ₩1.74 Trillion ≈ $1.18 Billion |
₩-124.96 Billion ≈ $-84.68 Million |
-0.072x | -121.41% |
| 2021-12-31 | ₩1.60 Trillion ≈ $1.09 Billion |
₩536.59 Billion ≈ $363.64 Million |
0.335x | -26.47% |
| 2020-12-31 | ₩263.79 Billion ≈ $178.77 Million |
₩120.22 Billion ≈ $81.47 Million |
0.456x | +386.10% |
| 2019-12-31 | ₩232.73 Billion ≈ $157.72 Million |
₩21.82 Billion ≈ $14.79 Million |
0.094x | +32.58% |
| 2018-12-31 | ₩210.73 Billion ≈ $142.81 Million |
₩14.90 Billion ≈ $10.10 Million |
0.071x | -- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more